Global Cytomegalovirus Infection Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Cytomegalovirus Infection Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Cytomegalovirus Infection Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2032

Global Cytomegalovirus Infection Market was valued at US $550.2 Million in 2022 and is expected to reach US $995 Million by 2032, growing at a CAGR of 6.1% during the forecast period 2023-2032.

A common herpesvirus infection, cytomegalovirus can cause a variety of symptoms, including fever, exhaustion, and severe symptoms that affect internal organs like the brain and eyes. Blood, semen, saliva, urine, and breast milk are among the bodily fluids that can spread the dangerous virus CMV. Antiviral drugs are usually used as the main form of treatment; they are useful in reducing the rate of virus replication but do not totally stop it. Treatment for cytomegalovirus usually involves the use of commercially available antiviral medications such as Ganciclovir, Foscarnet, Valganciclovir, Cidofovir, and others.

About 0.8% of the total revenue in the worldwide infectious disease diagnostics market is generated by cytomegalovirus treatment. The demand for cytomegalovirus treatment is expected to rise globally due to rising viral infection rates and rising knowledge of CMV symptoms. But it's crucial to remember that the market for CMV treatments is subject to swings driven by macroeconomic variables and industry norms, especially in light of the stringent laws regulating the creation, manufacturing, and licensing of biopharmaceuticals.

Due to the therapy's low efficacy in treating patients with severe immunosuppression or disseminated disease, the market's Business Performance Score (BPS) levels have decreased. Such instances have increased because to the global COVID-19 pandemic, highlighting the shortcomings of CMV treatment and causing a drop in BPS values that would hinder market expansion.

On the other hand, the market's prognosis has improved recently. This change is mostly attributable to the FDA's 2022 approval of the first medication intended for use in treating cytomegalovirus infections and illnesses in adults and paediatric children that cannot be adequately treated with presently approved antiviral treatment regimens. In the next years, there will be more potential for market expansion because to this development.

“Oral segment, by route of administration, to be largest market from 2023 to 2030.”

The segmentation analysis of the treatment type segment is as oral, parenteral and Others. Medication given orally in the form of pills, capsules, or liquid formulations is known as an oral treatment for CMV. There are oral versions of several antiviral drugs used to treat CMV, like valganciclovir. People can easily administer these at home, particularly for prophylactic or long-term treatment. Parenteral medications are given by injections, infusions, or intravenous techniques, which are channels other than the digestive tract. Intravenous administration of certain antiviral medicines for CMV, such as Ganciclovir or Cidofovir, occurs in hospital or clinical settings. This approach is frequently taken in circumstances that require rapid medical attention, are more severe, or involve people who might have trouble taking oral drugs. Alternative or specialised administration techniques that do not fall under the oral or parenteral routes may be included in the others segment. It may include less conventional drug delivery methods, experimental approaches, or novel CMV infection treatments that are being investigated or developed.

“Hospitals pharmacies segment, by end user, to be largest market from 2023 to 2030.”

The segment segmentation analysis of the end users is as hospitals, specialty clinics, homecare and others. Treatment for severe cases of CMV infection, particularly those that impact multiple organ systems or result in potentially fatal consequences, is largely handled in hospitals. Patients with serious CMV-related illnesses such CMV pneumonia or encephalitis can receive round-the-clock surveillance, intensive medical care, inpatient treatment, and access to specialised technology in hospital settings. Individuals with CMV infections are frequently served by specialised clinics devoted to virology or infectious illnesses. These clinics provide more specialised care, knowledge, and tailored treatment plans for the management of CMV, especially when it comes to conditions like CMV retinitis or ulcerative gastrointestinal tract infections. With home-based care, those infected with CMV can get supportive care, monitoring, and treatment in the convenience of their own homes. To manage the illness outside of a clinical or hospital setting, this may entail the delivery of oral drugs, specific care instructions, and routine check-ins by medical specialists. The ""others"" segment could include non-traditional healthcare settings like community health centres that offer information and support, research institutes that conduct clinical trials or studies linked to CMV, or non-profit organisations that support and advocate for people infected with CMV.

“North America to be largest region in Cytomegalovirus Infection Market.”

By region, the market is divided into North America, Europe, APAC, and Others. Others are further divided into the Middle East and South America.

It is projected that North America will continue to hold a sizable portion of the worldwide market throughout the forecast period. Market expansion in this region is anticipated to be influenced by a number of factors, such as the rising incidence of cytomegalovirus (CMV) infections, rising consumer awareness, and significant market players. For instance, according to a July 2022 NINDS post, CMV is one of the most prevalent congenital infections in the US, affecting between 50% and 80% of adults by the age of 40. Similarly, June 2021 statistics from CMV Canada showed that one in every 200 Canadian infants is born with CMV during pregnancy. The study also noted that one in five congenital CMV infections led to a lifelong handicap, such as delayed development or hearing impairment. On the other hand, a September 2022 BMC article reported that, among Mexican pregnant women, the seroprevalence of CMV infection in 2021 was significantly greater in those aged 30 to 39 (86.5%) than in those under 20. It is anticipated that the increased prevalence of CMV in North America will increase need for efficient treatment, driving market expansion.

Moreover, throughout the projected period, the growing number of product approvals meant to give patients safe and effective treatments is anticipated to propel market expansion. For example, in November 2021, Takeda Pharmaceuticals received FDA clearance for Maribavir, a medication intended to treat adults and paediatric patients 12 years of age or older who have a post-transplant cytomegalovirus infection or illness that is not responding to treatment.

Given these reasons, together with the rising incidence of CMV infections, the existence of major players in the market, and the regular improvements in product development, it is expected that the North American market will increase significantly in the near future.

Cytomegalovirus Infection Competitive Landscape

The competitive landscape of the Cytomegalovirus Infection Market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Cytomegalovirus Infection technology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Cytomegalovirus Infection Market is highly competitive, with numerous companies vying for market share. Prominent companies in the Cytomegalovirus Infection Market include:

Major Players:

Merck & Co. Inc.

Cell Medical Ltd.

Chimerix, Inc.

Affymetrix, Inc.

Abbott Laboratories, Inc.

Becton, Dickinson and Company

Johnson & Johnson

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche Ltd.

Recent Developments:

ProBioGen and the City of Hope signed a commercial licence deal in September 2022 to manufacture the Cytomegalovirus (CMV) vaccine using the AGE1.CR.pIX vaccine production platform.

Synklino completed a successful Series A fundraising round in June 2022, obtaining funds of EUR 29.8 million (USD 31.8 million). The cash will be used to advance the company's medicine candidate, SYN002, which is intended to fight the cytomegalovirus (CMV). The company specialises in creating pharmaceuticals for treating chronic viral infections.

The FDA approved LIVTENCITY (maribavir) in November 2021 for the treatment of post-transplant cytomegalovirus (CMV) infection in adults and paediatric patients who are not responding to ganciclovir, cidofovir, valganciclovir, or foscarnet. This announcement was made by Takeda Pharmaceutical Company Limited. As a novel molecular entity, LIVTENCITY inhibits nuclear egress, encapsidation, and viral DNA replication by targeting CMV through its impact on pUL97.